Department of Gastrointestinal Oncology
Cancers | Free Full-Text | Recent Developments of Systemic Chemotherapy for Gastric Cancer
Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial - The Lancet Oncology
Efficacy of Combination Chemotherapy Using a Novel Oral Chemotherapeutic Agent, TAS-102, with Irinotecan Hydrochloride on Human Colorectal and Gastric Cancer Xenografts | Anticancer Research
LONSURF® (trifluridine and tipiracil) tablets Efficacy | Previously Treated Metastatic GEJ and Gastric Cancer Treatment
Korean Practice Guideline for Gastric Cancer 2018: an Evidence-based, Multi-disciplinary Approach
Gastric Cancer Foundation lonsurf Archives | Gastric Cancer Foundation
Result of the PII trial of TAS-102 in third/fourth line colorectal... | Download Scientific Diagram
Novel oral chemotherapeutic holds potential for stomach cancer patients
Targeted and novel therapy in advanced gastric cancer | Experimental Hematology & Oncology | Full Text
LONSURF® (trifluridine and tipiracil) tablets Efficacy | Previously Treated Metastatic GEJ and Gastric Cancer Treatment
LONSURF® (trifluridine and tipiracil) tablets Efficacy | Previously Treated Metastatic GEJ and Gastric Cancer Treatment
Relative tumor volume (RTV) (a) and body weight change (BWC) (b) in... | Download Scientific Diagram
Gastric cancer: Translating novels concepts into clinical practice - ScienceDirect
Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial - The Lancet Oncology
Trifluridine/Tipiracil: A Review in Metastatic Gastric Cancer - YouTube
Dihydroartemisinin suppresses proliferation, migration, the Wnt/β‑catenin pathway and EMT via TNKS in gastric cancer Corrigendum in /10.3892/ol.2021.13152
Gastric Cancer Foundation FDA Grants Priority Review to TAS-102 for Gastric/GEJ Cancer | Gastric Cancer Foundation
TAGS: A Phase 3, Randomised, Double-blind Study of Trifluridine/Tipiracil ( TAS-102) Versus Placebo in Patients With Refractory Metastatic Gastric Cancer. - ppt download
Late-line treatment in metastatic gastric cancer: today and tomorrow | Semantic Scholar
Efficacy of trifluridine and tipiracil (TAS-102) versus placebo, with supportive care, in a randomized, controlled trial of patients with metastatic colorectal cancer from Spain: results of a subgroup analysis of the phase
New developments and standard of care in the management of advanced gastric cancer - ScienceDirect
